Trial Condition(s):

Non-Hodgkin's Lymphoma (NHL)

Zevalin post-marketing surveillance in Japan (ZEVALIN-DUI)

Bayer Identifier:

15042

ClinicalTrials.gov Identifier:

NCT01448928

EudraCT Number:

Not Available

Recruiting

Trial Purpose

This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin’s lymphoma and Mantle cell lymphoma. The objective of this study is to assess safety and efficacy of using Zevalin in clinical practice. This study is also all case investigation of which the enrollment period is five years, and all patients who received Zevalin will be recruited and followed 13 weeks after the administration.

Inclusion Criteria
Patients who received Zevalin for relapsed or refractory:
 -  CD20+
 -  low grade B-cell non-Hodgkin’s lymphoma
 -  Mantle cell lymphoma
Exclusion Criteria
-  Patients who are contraindicated based on the product label

Trial Summary

Enrollment Goal
400
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Zevalin (Ibritumomab tiuxetan, BAY86-5128)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Recruiting
 

Trial Design